16/12/2025 - Press release
It aims to develop the first treatment based on mRNA therapy to boost the efficacy of immunotherapy for this type of tumour. The new company, a spin-off of the Hospital del Mar Research Institute Barcelona, plans to launch its first human clinical trial in 2028 to validate the safety of this approach. The project is led by Drs. Toni Celià-Terrassa and Joan Albanell, pioneers in the development of nanotherapies designed to transform tumours that are resistant to immunotherapy into tumours that are vulnerable to treatment.
16/12/2025 - Press release
These are some of the conclusions of the report "Working on digital platforms: What do we know about health and safety?", a joint study by UPF and the Hospital del Mar Research Institute Barcelona, within the framework of the international project GIG-OSH, which has collected data from seven European countries.
12/12/2025 - Press release
Having a higher proportion of fatty acids in the blood from a healthy diet reduces the risk of suffering from this type of stroke by 14%. The researchers have established an index that measures more reliably than other systems used the quality of fats in the diet of the studied individuals. The work is published in the European Stroke Journal. Blood fat levels can be calculated from a simple blood test. This opens the door to its application in clinical practice.
Més informació "They design a tool to predict the risk of ischemic stroke from blood fats"
11/12/2025 - Press release
The research team led by the Institut de Recerca Joan de Déu (IRSJD) and the Hospital del Mar Research Institute has, for the first time, demonstrated the efficacy of a drug in animal models developed from samples of patients from the Sant Joan de Déu Hospital. The study identifies the PRKG1 gene as a key element in the biology of rhabdomyosarcoma and as a potential biomarker to predict treatment response. The determination of Cristina's parents-a girl who passed away from rhabdomyosarcoma in 2015-has been crucial in making this study possible. Their commitment enabled the raising of more than €600,000 to promote research into new treatments for this type of pediatric tumor.
04/12/2025 - Press release
A study from the Hospital del Mar Research Institute, published in The Journal of Clinical Investigation, indicates that the high expression of the estrogen receptor is the main factor preventing the most common type of breast cancer, luminal breast cancer, from responding to immunotherapy. The high presence of the estrogen receptor sequesters the LCOR molecule, whose action on tumor cells is necessary to make tumors visible to the immune system. In experimental models, the researchers found that combining immunotherapy with endocrine therapy allows LCOR to function and the immune system to attack the tumor. At the same time, they have generated a modified version of the LCOR molecule that sensitizes tumors to immunotherapy, including those with hormone receptors. The next goal is to study this molecule combined with immunotherapy in clinical trials.
20/11/2025 - Press release
This discovery, carried out by a multidisciplinary team led by researchers from the Hospital del Mar Research Institute and the Sant Joan de Déu Research Institute, opens the door to understanding the mechanisms that trigger tumour proliferation and to exploring potential therapeutic targets. Researchers suspect that the genetic alteration that activates the mechanisms behind this type of cancer occurs during embryonic development. Ewing sarcoma is a highly aggressive tumour that can affect bones and soft tissues, and is the most frequent bone tumour in childhood.
Més informació "Researchers identify the cell of origin of Ewing Sarcoma"
06/11/2025 - Press release
A systematic review of published studies on service coverage for these conditions in adults, published in The Lancet Regional Health - Europe, reveals this gap. Overall, there is little information about the capacity to provide care for people with mental disorders across European countries. Existing data show great disparities between nations and generally low coverage for nearly all disorders. These figures put at risk the World Health Organization's goal of increasing coverage for these patients by 50% by 2030.
31/10/2025 - Press release
An international study published in Brain, Behavior, and Immunity shows that patients with treatment-resistant depression (TRD) have a unique biology, different from those who respond to standard therapies. More than 5,000 genes were found to behave differently in TRD compared with non-resistant patients. The study reports the first results of the PROMPT consortium, which aims to combine clinical and molecular data using machine learning to predict which patients are at risk of developing TRD.
Més informació "Treatment-resistant depression identified as a distinct molecular subtype"
16/10/2025 - Press release
Greater exposure of mothers to airborne particulate matter during pregnancy is linked to lower levels of brain myelination in newborns. This is highlighted by the first study to measure neonatal brain myelination using magnetic resonance imaging (MRI). Published in the journal Environment International, it is the result of a collaboration between Hospital del Mar and ISGlobal. The research shows that prenatal exposure to fine particles (PM2.5) is associated with slower brain maturation during the first month of life. Myelination is a key marker of brain development.
10/10/2025 - Press release
Stress sensitivity increases the frequency, intensity, and variability of suicidal thoughts among the university community. These are the findings of a longitudinal study coordinated by the Hospital del Mar Research Institute and Pompeu Fabra University, which analyses survey data from more than 700 university students. The study defines, for the first time, three degrees of passive suicidal ideation according to their frequency, intensity and increasing variability. Taking stress sensitivity into account could have an impact on suicide prevention.
Servei de Comunicació:
Marta Calsina(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
